unknown
Research Passport
Lecanemab in Early Alzheimer's Disease.
The New England journal of medicine· 2023-01-05· unknown
Christopher H van Dyck, Chad J Swanson, Paul Aisen, Randall J Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, David Li, Larisa Reyderman, Sharon Cohen, Lutz Froelich, Sadao Katayama, Marwan Sabbagh, Bruno Vellas, David Watson, Shobha Dhadda, Michael Irizarry, Lynn D Kramer, Takeshi Iwatsubo
Stage: unknownIntegrity: okDOI: 10.1056/nejmoa2212948PMID: 36449413
PharmaLens analyzed the title, abstract, and available metadata—not the full text.
Discuss this paperOpens the Paper Discussion Hub (community opinions are not article intelligence)
Study design
Verified findings
numeric_findings[0]
{"unit":null,"label":"reported_value","value_text":"18"}
View evidence
CONCLUSIONS · CONCLUSIONS:S001
“”
numeric_findings[1]
{"unit":null,"label":"reported_value","value_text":"18"}
View evidence
METHODS · METHODS:S001
“”
numeric_findings[2]
{"unit":null,"label":"reported_value","value_text":"1"}
View evidence
METHODS · METHODS:S002
“”
numeric_findings[3]
{"unit":null,"label":"reported_value","value_text":"18"}
View evidence
METHODS · METHODS:S003
“”
numeric_findings[4]
{"unit":null,"label":"reported_value","value_text":"14"}
View evidence
METHODS · METHODS:S004
“”
population
{"description":"The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease.","sample_size":null,"exclusion_summary":null,"inclusion_summary":null}
View evidence
BACKGROUND · BACKGROUND:S001
“”
Limitations & not reported
- authors_conclusion
- comparator
- intervention
- key_results
- limitations
- primary_outcome
- safety_findings
AI transparency & provenance
- PharmaLens analyzed the title, abstract, and available metadata—not the full text.
- This page is not medical advice.
- Scores and ranks shown in search are query-relative relevance only — not evidence quality.
- Similarity neighbors do not imply support or contradiction.
- Cover media kind: deterministic_cover
- Extraction schema: pharmalens.article-intelligence.v1
- Revision: 1
Cite this page
Related research
- Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial.
- Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
- Evidence Neighborhood preview: Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
- Evidence Neighborhood preview: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- Evidence Neighborhood preview: Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
- Evidence Neighborhood preview: Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial.
Relatedness is similarity or shared entities — not support or contradiction.